inVentiv Health Clinical releases new tool to connect physicians participating in late-stage research

inVentiv Health Clinical, a leading global supplier of drug development services, today announced the launch of an innovative, web-based network to efficiently connect physicians interested in participating in late-stage research to appropriate clinical trials.

The inVentiv Physician Network (inVentivDocNet.com), a crowdsourcing tool, promises to help research sponsors accelerate study enrollment. It is part of inVentiv Health's broad strategic investment in innovation to speed clinical trials.

"We believe physicians will find this a valuable new channel for accessing 'real-world' research opportunities," said Jeff Trotter, inVentiv Health Clinical Executive Vice President – Late Stage. "The inVentiv Physician Network welcomes virtually any clinician who seeks to participate in observational research, including patient registries, safety surveillance programs, postapproval safety studies, and other noninterventional and quality-of-life studies."

By joining the network, physicians can find easy-to-manage research opportunities involving approved products used in everyday practice. Sponsors can access the busiest and most relevant practicing physicians for their studies, accelerating both site and patient enrollment. Together, physicians and sponsors can generate real-world information that is critically important in establishing the value of medical treatments and procedures.

The inVentiv Physician Network complements inVentiv's other innovations in clinical trial recruitment. inVentiv Clinical Trial Recruitment Services (iCTRS) uses behavioral research, proprietary data, and cutting-edge technology to improve feasibility, enrollment, and patient recruitment. Mytrus Inc., in which inVentiv has acquired an equity stake, has pioneered electronic informed consent to improve trial efficiency and patient retention.

"With the inVentiv Physician Network we bring more and more physicians the opportunity to contribute vital new data to the medical community by participating in important new studies that capture real-world patient experiences and clinical outcomes," Trotter said.